Concurrent chemotherapy plus cetuximab or chemotherapy followed by cetuximab in advanced non-small cell lung cancer (NSCLC): A randomized phase II selectional trial SWOG 0342
Kelly K, Herbst R, Crowley J, McCoy J, Atkins J, Lara P, Dakhil S, Albain K, Kim E, Gandara D. Concurrent chemotherapy plus cetuximab or chemotherapy followed by cetuximab in advanced non-small cell lung cancer (NSCLC): A randomized phase II selectional trial SWOG 0342. Journal Of Clinical Oncology 2006, 24: 7015-7015. DOI: 10.1200/jco.2006.24.18_suppl.7015.Peer-Reviewed Original ResearchNon-small cell lung cancerAdvanced non-small cell lung cancerPhase II trialII trialLarge randomized phase II trialRandomized phase II trialSmall-molecule EGFR tyrosine kinase inhibitorsEGFR tyrosine kinase inhibitorsAdequate organ functionPhase III settingPhase III trialsYears of therapyCell lung cancerRandomized clinical trialsMolecular correlative studiesTyrosine kinase inhibitorsAnti-tumor activityTrue hazard ratioConcurrent chemotherapyConcurrent regimenEligible ptsPrimary endpointStage IIIBUntreated patientsHazard ratio